Inmune Bio to Host Webinar Presenting New Phase III CORDStrom Data for RDEB

summarizeSummary

Inmune Bio announced an upcoming webinar to present new Phase III clinical data for its CORDStrom™ program in recessive dystrophic epidermolysis bullosa (RDEB), highlighting systemic disease-modifying capabilities and key clinical benchmarks.

check_boxKey Events

• Webinar to Present Phase III CORDStrom Data

  Inmune Bio will host a webinar on February 26, 2026, at 1:00 p.m. ET to present new clinical data from the MissionEB Phase III clinical trial for CORDStrom™ in recessive dystrophic epidermolysis bullosa (RDEB).

• Focus on Systemic Disease-Modifying Capabilities

  The webinar will highlight CORDStrom's systemic, disease-modifying potential, moving beyond topical wound treatments, which is a significant advancement for RDEB patients.

• Presentation of Key Clinical Benchmarks

  New data will be shared on EBDASI Skin Score improvements, nutritional and weight gain in pediatric patients, reductions in pain and itch, and enhanced quality of life for RDEB patients.

auto_awesomeAnalysis

This filing announces a significant upcoming event for Inmune Bio, as it details a webinar to present new Phase III clinical data for its CORDStrom™ program in recessive dystrophic epidermolysis bullosa (RDEB). For a clinical-stage biotechnology company, Phase III data is paramount, representing the final stage before potential regulatory submission. The specific focus on systemic disease-modifying capabilities and key clinical benchmarks like EBDASI improvements, nutritional data, symptom reductions, and enhanced quality of life suggests the company anticipates positive results. This event builds on the recent 8-K filings from January 27 and February 13, which highlighted general clinical and regulatory progress. Given the company's stock is currently trading near its 52-week low, the presentation of compelling Phase III data could serve as a crucial catalyst for investor sentiment and valuation.